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Abstract 
Ductal carcinoma in situ (DClS) is composed of clonally proliferative malignant 
mammary ductal epithelial cells within the mammary duel lumen without 
breaching the basement membrane. It is a preinvasive malignancy with very rare 
existence of lymph node metastasis. Therefore the rationle in treating DCIS is to 
prevent the progression into an invasive ductal carcinoma. The Modified Van 
Nuys Prognostic Index (VNl)l) introduced in 2003, based upon tumor size, 
pathological grade (based on nuclear grade and comedo necrosis), tumor 
margins and age, serves as a guideline for the treatment of DCIS. Given a score 
for each predictors (from 1 to 3 i.e. most favorable to most unfavorable), 
different regimen of treatment will be advised to patients according to the 
grading. It aims to prevent overlreatment and at the same time impede 
progression of the preinvasive tumor to an invasive one. 
However, the accuracy of the VNPI in predicting invasive recurrence is 
controversial and there is an urge to identify biological markers in creating a 
prognostic profile. In the project, we try to study the biology of DCIS by 
screening some potential biological markers. 
In this study, formalin-fixed paraffin embedded (FFPE) breast tissue was 
obtained from 213 patients diagnosed as pure DCIS. RNA was extracted from 
the tumor tissues and its adjacent normal tissue which served for comparison. 
First-strand cDNA was synthesized with random primers, and PGR was 
performed using designed primers upon genes of interested. According to the 
PGR results, statistical analysis was performed using chi-square and binary 
logistics regression. This project aims to find out potential molecular prognostic 
markers which are grade specific for DCIS, so as to lead to a more effective 
treatment with minimization of morbidity. Together with the current 
morphologic grading, stratification of patients into different categories and 
application of appropriate Irealmenl protocol accordingly is our ultimate goal. 
In this study, two out of 46 genes demonstrated their potential to be the DCIS 
markers, namely ETV6 and Erbb2. They showed statistical significant 
correlation in expression in different DCIS grading in the tumor tissues 
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Chapter 1 Introduction 
1.1 Breast cancer overview 
Cancer occurs when cell in a pari of the body grows out of control, instead of 
grow and divide in an ordered fashion. Breast cancers thus refer to those 
arising from the breast tissue, including the terminal lobular duel unit and the 
intervening stroma. Those arising from the epithelial component significantly 
outnumber those from the mesenchymal tissue. According to the International 
Agency for Research on Cancer in 2003, breast cancer is the second most 
common type of cancer among all cancer incidcnce, and the firth most common 
cause of cancer death. If consider the women population only, breast cancer 
ranks the top. 
There is distinct regional difference in the incidence of breast cancer. Women 
in the developed countries (e.g. North America, Northern Europe, Western 
Europe and Oceania) are more vulnerable to breast cancer than those living in 
the developing countries (e.g. South Central Asia. Africa and South America) 
(Fig. 1.1). Both men and women are susceptible to breast cancer, and a clear 
excess of cases involving the female. It is about 100 times more common 
among women than men. Breast cancer accounts for less than 1% of cancer 
deaths among men. 
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In East Asia region including Japan and China, the incidence of breast cancer is 
increasing which is believed to be caused by the influence of modem western 
lifestyles. In addition, there are a number of well known risk factors for the 
development of breast carcinoma, the most common breast cancer, such as older 
age, early menarche, late menopause, nulliparous, family history, radiation 
therapy to the chest, obesity, long term intake of hormone-related drugs, etc. 
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Fig 1.1 Compar ison of common cancers in women in more and less developed countries. 
Source: World Cancer Report 2003 
iii 
foi ^HBHHHHHr i ^ ^ ^H I 
49« mmi i i i i l i ^ ^B^B MS 
Cfllomctjm 
J17 
M2 • ^ • • • • • l 
Corvix utwi " 。 
Owttohuui m U l i f MO 
24, ^ • • l n 
•如 r tfHaa 
1 “ •HBH 120 
S9n-Hortekin lymptwma 
l ‘9 • • • • 97 
U4 • • • I tl2 
丨 “ 一 im1V*S 
m 100 
g p ,01 
11« _ 70 CSSI 
‘ . , “ ， … ‘ … • i • … ‘ … • 一 • ’ Number (thousand) 
Fig 1.2 Compar ison of incidence and mortality of the most common cancers worldwide. 
Source: World Cancer Report 2003 
In the 1980s, screening mammography for routine breast examination in 
asymptomatic women became widely accepted and utilized (Blackman D.K. et 
al, 1999; Sue A. et al, 2006). As a result of improved screening, the proportion 
of women diagnosed with DCIS increased significantly during this time period 
(Wun L.M. et al, 1995) and comprised a growing subset of breast cancer 
diagnoses worldwide (LeRon C.J. et al, 2007). 
In the US, approximately 25% of new cases of breast cancer were classified as 
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DCIS (Silverstein M.J. et al, 2005), with an incidence rate between 15 to 17 out 
of 100,000 (Levi F. et al, 1997). In Norway, since the launch of Norwegian 
Breast Cancer Screening Program in 1995, the proportion of DCIS among breast 
cancer cases was 5% in the pre-screening period and 14% in the screening 
period (Hofvind S. et al, 2008). For New South Wales (NSW) women in 
Australia, there was an incidence rale of 8.6 out of 100, 000 women and 
interestingly a 25% higher in urban than rural areas of NSW and increased 
strongly with increasing socio-economic status in Sydney (Kricker A. et al, 
2004). Meanwhile, in Singapore, it was reported that the breast cancer incidence 
has increased since the launch of the Singapore Breast Screening Project 
including the DCIS incidence rates (Shanika M. et al, 2006). There was no 
publication so far indicating the DCIS incidence rate in Hong Kong. 
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1.2 General mechanism of breast carcinoma 
Under normal circumstances, benign ductal epithelial cells differentiate and 
proliferate within the confine of the basement membrane of the mammary ducts. 
However, when one or more cells lose normal cellular biology and become 
dysplastic, they proliferate within the ducts with or without distension of the 
ductal 丨umina, and eventually these cells invade through the basement 
membrane. Thereafter they invade into the breast stroma and reach the 
lymphovascular 1 umina and perineural spaces, and metastasize to other parts of 
the body ((Fig. 1.3 to 1.6). 
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Source of images: http://mcb.bcrkcley.edu/courscs/mcb41/BrcastCancer.pdf 
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1.3 Ductal carcinoma in situ (DCIS) 
DCIS is a neoplastic intraductal lesion characterized by increased epithelial 
proliferation, subtle to marked cellular alypia and an inherent but not necessarily 
obligate tendency for progression to invasive breast cancer (Vang R. et al, 2003). 
Thus it is considered as the pre-invasive stage of breast cancer as the cancerous 
breast duct epithelial cells have only clonally 丨proliferated and accumulated 
within the mammary duct lumen (Vassiliki L. et al. 2006). As the disease 
progress, about half of them develop lo invasive breast cancer (Bijker N. et al, 
2001). 
1.3.1 Clinical features of DCIS 
The major clinical findings of DCIS include palpable lumps, pathologic nipple 
discharge, nipple alterations associated with Paget disease. With the help of 
screening mammography, a number of symptomless DCIS are detected as well. 
In countries where population screening is performed, the vast majority of DCIS 
are actually detected by imaging alone. Only approximately 10% of DCIS are 
associated with some clinical findings and 5% is detected incidentally in 
surgical specimens (Vang R. et al, 2003). 
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1.3.2 Classification of DCIS 
DCIS used to be classified according to its architecture (comedo, cribriform, 
papillary, micropapillary and solid)，nuclear grade, polarization, and necrosis. 
Recently, in order to gain a better prediction in the disease recurrence after 
surgical resection, information of nuclear grade, cell polarization and necrosis 
are highly regarded. This advancement was made in 1995, when the Van Nuys 
Prognostic Index (VNI)I) was introduced by Silverstein (Silverstein M.J. et al, 
1995) to predict the likelihood of tumor recurrence. 
The Van Nuys Prognostic Index (VNPl) 
Under this classification system, the size oHX' lS , nuclear grade, and presence 
and absence of necrosis are taken into consideration in the prediction of 
recurrence of tumor after surgical resection. 
The VNPI scored from 1 to 3 according to the tumor size, nuclear grade, 
presence of necrosis, and the extent of tumor-free margins. The most 
important parameter in the scoring is the nuclear grade, while the nucleus is 
being categorized into to low, intermediate or high (Bellamy C.O. et al, 1993). 
For low grade DIGS (Fig. 1.7), it is expected to observe small nuclei with 
monotonous appearance, diffuse chromatin and few mitotic figures, and sized 
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about 1.5 to 2 times of red blood cell (RBC). For high grade DCIS (Fig. 1.10, 
1.11), it is expected to see larger pleomorphic nuclei, with irregular chromatin 
distribution and prominent mitotic figures and sized about 2.5 to 3 times of 
RBC. For the intermediate nuclei (Fig. 1.8，1.9), they belong to neither of the 
above groups (Table 1.1 and 1.2). In general, the higher the nuclear grade, the 
higher the chance of recurrence after surgical excision (Vassiliki L. et al, 2006). 
Necrosis is of the next importance, ll refers to the comedo-type necrosis seen 
in the center of the lumen. 
However, no matter under which classification system is applied, the DCIS 
biological potential in progression to invasive cancer yet remained unknown 
(Silverstein M.J. et al, 1996). 
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Nuclear grading Features 
Grade I 1.5 - 2.0 normal RBC 
Grade II Between Grade I and III 
Grade III Nuclei usually >2.5 RBC 
Table la. Tumor j»radiiig in tumor cells 
Grading Features 
Low Grade DCIS with grade I/II nuclei, without necrosis 
Intermediate Grade DCIS with grade l/ll nuclei, with necrosis 
High Grade Any DCIS with grade III nuclei, with/without necrosis 
Table lb. The Van INuys Grading System in DCIS classification 
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Fig. 1.7 Low grade DCIS (200X) The nucleus of the cells (green arrow 
were about 1.5 times of the R B C (orange arrow). 
Fig. 1.8 Intermediate grade DCIS (lOOX) The nucleus of the cells (green 
arrow) were between 1.5 to 2.5 times of the R B C (orange arrow), i.e. 
between Grade I and I I I . Necrosis (Blue arrow) was seen in the centre of 
lumen and was another important feature of DC IS clas^ijTication. 
• . ' . . 
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Fig. 1.9 Intermediate grade DCIS , without necrosis (400X). The 
nucleus of the cells (green arrow) were between 1.5 to 2.5 times of 
the R B C (orange arrow), i.e. between Grade I and I I I . No necrosis 
was seen in the lumen. 
Fig. 1.10 High grade DCIS (lOOX) The nucleus of the cells (green arrow) were 
>2.5 times of the R B C (orange arrow). Necrosis (Blue arrow) was seen in the 
centre of lumen and was another important feature of DCIS classification. 
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Fig. 1.11 High grade DCIS , without necrosis (400X) The nucleus of the 
cells (green arrow) were >2.5 times of the R B C (orange arrow). 
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1.3.3 Molecular markers for DCIS 
1.3.3.1 Mutation of p53 
p53 is a nuclear protein which plays an essential role in cell cycle regulation and 
plays a role in the GO to G1 transition. It has a high expression in transformed 
cell lines and but not in normal cells, thus considered contribute to 
transformation and malignancy (Janicke R.U. et al, 2008). Normally, p53 is 
believed to inhibit tumor growth and invasion through activation of its 
downstream genes, such as genes responsible for cell cycle arrest, DNA repair 
and apopotosis (as shown in Fig. 1.12). The following flow-chart describes the 
functional pathway of p53: 
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Fig. 1.12 F l ow d i a g r a m s how i ng the n o r m a l p53 p a t h w a y 
Sourcc of image : http://p53.frce.fr/p53—info/p53_info.html 
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Fig. 1.13 Diagram showing the normal p53 pathway. p53 keep cells from 
progressing through the cell cycle upon damaged and is achieved 
through phosphorylation regulation. The above diagram showed the 
halting of cells at checkpoints for repairing or cells will be made to enter 
apoptosis. 
Source of image : http://www .biocarta.com/pathfiles/h_p53Pathway.asp 
However, upon mutation, the tumor suppression function of p53 was lost and 
promoted tumor growth due to loss of normal cell cycle regulation (Ichikawa A. 
et al, 2008). While in DCIS, mutation of p53 has a high correlation with nuclear 
grade and comprised of about 25% of all DCIS lesions (Rudas M. et al 1997). 
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In a recent study, it showed p53 mutation resulted in genetic instability and 
increased abnormal cellular features, and finally caused well-differentiated 
DCIS to evolve to poorly differentiated DCIS. This further proved the 
significance of p53 mutation as a molecular marker for DCIS (Allred D.C. et al 
2008). 
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1.3.3.2 Amplification of Erbb2 
Erbb2 is also known as 'HER 2’ or 'C-erbb2'. It encodes a member of the 
epidermal growth factor (EGF) receptor family of receptor tyrosine kinases 
(Cobleigh, M.A. et al, 1999). It enhances kinase-mediated activation of 
downstream signalling pathways by stabilizing ligand binding through forming 
heterodimer with other ligand-bound EGF receptor family members (Gschwind 
A. et al, 2003). 
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Fig . 1.14 D i a g r a m s h o w i n g the n o r m a l E r b b 2 p a t h w a y 
Source of image : http://www.liidwig.edu.au/CRC-CGF/resear6.jpg 
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Erbb2 over expression has an inverse correlation with estrogen and progesterone 
(ClasLi E.B. et al, 1995) and increases angiogenesis in DCIS cases suggested 
driving tumor cells towards malignancy (Vazquez M.A. et al, 2008). Its over 
expression is being seen in about 15-20% of breast cancer cases (Entrez Gene: 
Erbb2). As for cases of DCIS, it demonstrates in about 30% of DCIS cases 
and mostly in high grade DCIS (Leal C.B. et al, 1995). It is also correlated 
with increased metastatic potential and decreased patient survival (Cobleigh 
M.A. et al, 1999). 
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1.3.4 Progression of DCIS 
Researchers mostly support the theory of either the linear progression of DCIS 
from low to high grade, or the mutation of low grade DCIS to high grade 
(Vassiliki L.T. et al, 2006). The linear progression model was supported by an 
intracellular homeostasis modulator study on heat shock protein (hsp) 27. The 
hsp27 level is 7.4% in normal epithelial cells to 25.17% in epithelial cells with 
hyperplasia to 61.1% in epithelial cells among the DCIS cases. It postulated 
that there might be other protein expression acting similar to hsp27 and has 
significant correlation with DCIS progression (O'Neill P.A. et al, 2004). 
The other proposed DCIS progression model depends on the chromosome 
； 
deletion of low grade DCIS. For the low grade DICS that is associated with 
the loss of long arm chromosome 16, they are unlikely to develop into invasive 
tumor and vice versa as most high grade DCIS do no show these chromosome 
loss. Upon the postulalion of this hypothesis, a research team has further 
shown thai low-aggressive and high-aggressive DCIS could proceed in parallel 
steps, the former to become well differentiated carcinoma and latter to become 
poorly differentially invasive breast cancer (Gupta S.K. et al, 1997). The exact 
mechanism of DCIS progression is not yet established and subjected to further 
exploration. 
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1.4 Aim of project 
For decades the progression of pre-invasive DCIS to invasive carcinoma 
remained to be elucidated as the mechanism of this progression still remained 
unknown. 
The incidence rate of DCIS is on increasing trend due to the promotion of 
screening mammography and brings allenlion to the publics about the issue of 
breast cancer with emphasis on an earlier detection and curing has a significant 
decrease in disease recurrence and mortality. 
Despite with the grading of DCIS under I he Van Nuys Grading System, it gives 
only prediction to local recurrence of breast cancer with the biology of DCIS in 
progression to invasive carcinoma remained unknown. 
This project aims to find out potential molecular markers which are grade 
specific for DCIS, so as to lead to a more effective treatment with minimization 
of morbidity. Together with the current morphologic grading, stratification of 
patients into different categories and application of appropriate treatment 
protocol accordingly is our ultimate goal. 
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Chapter 2: Materials and Methods 
2.1 Categorization of DCIS Samples using Van Nuys Grading System 
Collection and Categorization of DCIS samples 
The histopathology files of the Prince of Wales Hospital and Kwong Wah 
Hospital were searched for DCIS cases, and all the slides were retrieved and 
reviewed by a pathologist. The cases were excisions, needle core biopsies or 
mastectomy, and the specimens had been fixed in buffered formalin, and 
routinely processed and stained with H&E. During histological review, only 
cases with pure DCIS without invasive component were included in the study. 
The nuclear grades were assessed upon comparison of the cells to the 
surrounding normal red blood cells (RBC), and classified as Grade I (1.5-2 
times of RBC), Grade II (2-2.5 times of RBC) and Grade III (2.5-3 times of 
RBC) nuclei. According to the nuclear grades, the cases were categorized into 
'Low' (with Grade I nuclei), ‘Medium’（with Grade II nuclei) and 'High' (with 
Grade III nuclei) grades according to the Van Nuys Grading system. 
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2.2 RNA extraction and reverse transcription of formalin-fixed, paraffin 
embedded (FFPE) DCIS samples 
2.2.1 Formalin-fixed, paraffin-embedded (i-l-PH) DCIS tissues 
Due to a substantial archive of tissue available, FFPE tissue remains the best 
method of preparation for microscopic examination in a routine clinical 
environment (Chung J.Y. et al, 2006). Also, FFPE samples provide abundant 
material for large and uniform retrospective studies as the FFPE tissues could be 
stored lor years (Maria R. et al, 2008). This explained the wide use of FFPE 
tissues for studies of human disease (Penland el al, 2007). To obtain accurate 
and relative gene expressions that directly linked to function data, and to save 
effort in analyzing unrelated and uninfornialive genes to decrease background 
noise (Cicaliello et al, 2004; Scafoglio el al. 2006), FFPE samples were chosen 
in the study. Among the samples included in the study were collected from 1999 
10 2007. 
In recent years, laboratory technology has significantly expanded the scope for 
heterogeneous FFPE material to be used in molecular research (Rogerson L. et 
al, 2008). Among the techniques, reliable transcript detection real-time PCR was 
shown in different FFPE tissues (Spcchl K. et al, 2001, Abraham sen H.N. et al, 
2003). It is because real-time PCR uses small amplicon sizes which are more 
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suited to the short templates derived iVoni degraded RNA as compared with 
standard PCR (Rogerson L. et al, 2008). 
In light of the application of small amplicon sizes, due to the partial mRNA 
degradation, on the sensitive real-time PCR, RNA was extracted from FFPE 
DCIS samples and reverse transcribed to cDNA for further studies. Thus, a 
molecular instead of a traditional immunohislochemical approach will be taken 
on the FFPE samples in the DCIS marker study. 
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2.2.2 Tissue Microarrav (TMA) 
Although introduced less than a decade ago, TMA has proven to be invaluable 
in the study of tumor biology, the development of diagnostic tests, and the 
investigation of oncologic biomarkers (Voduc C. el al, 2008). This allowed 
large-scale retrospective cohort studies using archival formalin-fixed, 
paraffin-embedded tissues (Camp R.L. el al, 2000). The major drawback of this 
technique was only a core of tissue section was analyzed and might not totally 
be representative of the tumor expression patterns. 
Three tissue core specimens (2mm in diameter) were taken from individual 
paraffin-embedded breast carcinomas and corresponding nonnal breast tissues 
and arranged in a new recipient paraffin block. This provided an efficient way to 
construct a DCIS data base as one recipient block contained up to 50 cases and 
facilitated screening for potential markers by various mechanisms (Dhir R. 
2008.). 
2.2.3 RNA Extraction 
After the TMA construction, pieces of tissue array block were cut and further 
divided into separate cases, 4 pieces of 15).im sections of each TMA sample 
were cut and placed into a sterile, RNasc-free 1.5ml microcentrifuge tube for 
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RNA extraction. The extraction was performed according to the PureLink「M 
FFPE Total RNA Isolation Kit (Invitrogcn, U.S.A.). (Fig 2.1) 
First melting buffer was used to melt the paraffin. Then the samples were lysed 
with Protein/RNase degrader, purified and washed and finally RNA was eluted 
with the RNase-Fi.ee Water provided by the PureLink™ FFPE Total RNA 
Isolation Kit. 
The quality of the RNA was assessed by checking lor genomic contamination 
by running PCR, using the extracted RNA as template and was run with the 
primers of the potential DCIS markers. All samples were then kept at -80°C 
until use. 
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Fig 2.1 Flow of RNA extraction from FFPE samples 




2.2.3.1 RNA quality of FFPE tissues 
RNA expression analysis is an important tool in cancer research, high-quality 
RNA are generally derived from frozen samples and posed limitations in such 
area. Such tumor sets are often small and lack clinical annotation, whereas 
formalin-fixed paraffin-embedded (FFPE) materials are abundant (Penland et al, 
2007). However, degradation of RNA during fixation and storage makes 
FFPE-derived RNA extraction challenging (Bibikova et al, 2008). In a study 
regarding prostate cancer, total RNA was extracted from FFPE biopsies and 
frozen control biopsies. The FFPE biopsies showed RNA with 100 to 300ng 
range while frozen biopsies could reach 500 to 750ng of RNA from each sample 
(Rogerson L. el al, 2008). 
Despite of RNA degradation, FFPE tissue provided invaluable information in 
diseases diagnosis. Recently, studies have perfornied and achieved remarkable 
progress to extract informative RNA from paraffin blocks (Cronin M. et al, 2004; 
Gloghini A. et al, 2004). Despite the less than 300 bases RNA fragments, it 
could be extracted and amplified by RT-PCR reactions. This has led, for 
example, to the construction of a real-time PCR-based model for prediction of 
recurrence in tamoxifen-trealed, node-negative breast cancer patients (Paik S. et 
al, 2004). 
2 7 
2.2.3.2 Validation of RNA quality 
To test for genomic contamination, PCR was run using RNA as templates and 
with the primers of the potential DCIS markers with the conditions same as the 
later PCR screening. That was, reactions were prepared in 0.2ml thin-walled 
containing 5^1 of PCR Master Mix (Promega), 0.2|.il for each of the forward and 
reverse primers, 2\.\\ of RNA template and the remaining adjusted to 10|_il 
volume by nuclease free water. 
The activation step was a hot start reaction at 95°C for 10 min, and then the 
thermal cycle conditions for amplification phase consisted of 40 cycles of 45s at 
95°C, 1 min at 58°C and 1 min at 72°C. The PCR products were resolved on 2% 
agarose gel. No bands should be observed in samples free from genomic 
contamination. 
To further ensure the RNA extracted was free from genomic contamination and 
the significance of real-time PCR results, real-lime 1)CR was run with the raw 
RNA was used as template. The conditions for the RNA check were the same as 
the later real-time PCR analysis :10 |il of SYBR Green PCR Master Mix 
(Applied Biosystems), 0.2|il for each of the forward and reverse primers, 3 |il of 
raw RNA template and the remaining adjusted to 20).il volume by nuclease free 
water. Triplicates of samples were prepared and P-actin was used as 
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normalization of respective gene expression. 
The conditions of the real-time RT-PCR were first activated to 95°C for lOmin. 
Then it was 44cycles of amplification steps (Fig. 2.1): 95°C (denaturing) for 30s, 
specific annealing temperature for 30s, 72°C (extention) for 30s. Finally it was 
the dissociation curve. 35 successive 30s plateaus incubation at 58°C with 
temperature increased by 1°C for each plateau was performed after the 1-min 
95°C incubation. Cycle thresholds (Ct) were determined by the instrument. 
Undetectable signal or signals of high Ct Values (>40 cycles) would be expected 
if samples were free from genomic contamination.. 
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2.2.4 First strand cDNA synthesis 
RNA (l|ig) was reverse transcribed in a 30(.il reaction for 1 hour at 42°C. The 
reaction mix consisted of 40pmol of oligo dT primer (Qiagen), 2|il of 
Improm-II reverse reanscriptase in 8 |il of Improm-lliM 5X reaction buffer, 
4.8|il of 25mM MgCl, 2|.il of 0.5mM clNTP (Qiagen), 30U of RNaseOUT™ 
(Invitrogen) and final volume adjusted lo 30|il by auloclaved distilled water. 
The synthesized first strand cDNA was used for the later PGR screening and 
real-time analysis after quality assessed by p-actin check (F: 
CTGGCACCCAGCACAATG; R: GCCGATCCACACGGAGTACT), of which 
the primers flanked the ex on region giving a 69bp amplicon which further 
confirmed the absence of genomic contamination in the RNA samples, and 
quality of cDNA could be further assured. 
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2.3 PCR screening for potential DCIS markers 
To look for potential DCIS markers, PCR was run to observe the expression 
patterns of particular genes in both the tumor and adjacent normal tissues of 
different DCIS grading for comparison. Primers were designed upon interested 
genes and sequences were provided by the kind sharing of Dr. Kornelia Polyak, 
Principal Investigator at Department of Medical Oncology, Dana-Farber Cancer 
Institute and her research team (Yao J. el al., 2006). The panel of genes was 
selected upon their amplification amplitude, frequency data, their know cancer 
candidacy and their potential role in DCIS. For some of the genes, several 
primers were designed to confirm amplification/expression. The sequences of 
primer sets are shown in Table 2.1. 
With the first strand cDNA synthesized previously as template, PCR was run 
using designed primers upon interested genes. 
Reactions were prepared in 0.2ml thin-walled containing 5|il of PCR Master 
Mix (Promega), 0.2f^l for each of the forward and reverse primers, 2[i\ of cDNA 
template and the remaining adjusted to 10f.il volume by nuclease free water. 
The activation step was a hot start reaction at 95°C for 10 min, and then the 
thermal cycle conditions for amplification phase consisted of 40 cycles of 45s at 
95。C, 1 mill at 58°C and 1 min at 7TC. The PCR products were resolved on 2% 
3 1 
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2.4 Statistical analysis of PCR expression patterns 
The data were analyzed with a binary input by detecting the 'presence' or 
'absence' of bands resolved on the agarose gel. Chi-square, binary logistic and 
ordinal regression were applied to analyze the results. 
2.4.1 Chi-square test 
In the probability theory and statistics, the chi-square distribution is one of the 
most widely used theoretical probability distribution in inferential statistics. The 
best-known situations in which the chi-square distribution used are the common 
chi-square tests for goodness of fit of an observed distribution to a theoretical 
one, and of the independence of two criteria of classification of qualitative data. 
(Johnson et al, 1994). 
In the study, chi-square was chosen as one of the preliminary analyses was 
because of its ability to observe the actual gene expression to theoretical gene 
expression in samples of different DCIS grades. Chi-square was run to analyze 
the gene expression on tumor samples and its respective adjacent samples. 
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2.4.2 Logistic regression 
For logistic regression, it is used for the prediction of the probability of a 
particular gene expression in certain DCIS grade. Logistic regression is being 
considered as a less stringent requirement as requires no normally distributed, 
linear or homoscedastic relationship between the dependent and independent 
variables. For the dependent variable, there should be only one of it thus 
continuous variables could not be used in logistic regression. 
With the use of this statistical lest, the percent of variance between the 
dependent and independent variable, relative importance of independents or 
interaction effects could be assessed (David G.G., 2008). 
Observations were expected to be independent and that the independent be 
linearly related to the logit of the dependent. Models would be constructed and 
the probability of patients having DCIS could be predicted with the following 
calculation: 
2 = /^ O + A ^ I + + H h ik^k^ 
while the variable z is a measure of the total contribution of all the risk factors 
used in the model and is known as the logit; B denoted the coefficient provided 
by the analysis results and x denoted the risk factor (0 is the absence of band and 
1 is the presence of bands). Then upon transformation of the logit z using the 
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following equation: 
l og i t (P i ) = 111 f y ^ ) = I h + l ^ i X l , + - • • + 
\ 1 ~ Pi/ 
the probability of patients having DCIS could be calculated. 
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2.5 Real-time RT-PCR analysis of the expression pattern of the potential 
DCIS marker 
2.5.1 Real-time RT-PCR for FFPE samples 
Gene expression quantification is important in understanding disease 
pathogenesis as gene expression pattern are frequently observed in diseases 
processes (Thomas G.R. el al, 2005; Lossos l.S. el al, 2006). Real-time PCR is 
the most sensitive and quantitative method to detect specific mRNA and is 
widely adopted for gene expression analysis. 
RNA extracted from formalin-fixed tissues was limited to small fragments and 
sensitivities in transcript detection were much worse than in fresh material 
(Godfrey T.E. et al, 2000). While for real-time PCR, it allows the amplification 
of short DNA fragments with high sensitivity, thus able to overcome the 
technical problem of RNA quality extracted from FFPE samples. 
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2.5.2 Real time RT-PCR in the study 
Reactions were prepared in 0.2ml thin-walled optical grade PCR tubes with flat 
caps and the application of the following components: 10 ).il of SYBR Green 
PCR Master Mix (Applied Biosyslems), 0.2|.il for each of the forward and 
reverse primers, 3 |.il of cDNA template and ihe remaining adjusted to 20|il 
volume by nuclease free water. Triplicates of samples were prepared and (3-actin 
was used as normalization of respective gene expression. 
The conditions of the real-time RT-PCR were first activated to 95°C for 10min. 
Then it was 44cycles of amplification steps (Fig. 2.1): 95°C (denaturing) for 30s, 
specific annealing temperature for 30s, 72°C (extenlion) for 30s. Finally it was 
the dissociation curve. 35 successive 30s plateaus incubation at 58°C with 
temperature increased by 1°C for each plateau was performed after the 1 -min 
95°C incubation. Cycle thresholds (Cl) were determined by the instrument. 
P-actin was being used as control in determining the Ct as the expression of 
P-actin shows little variation under DCIS stages. Normal breast tissues were 
used as control for normalization of expression level. 
Ratio (R) of the target gene expressed in a sample versus control was compared 
to the reference gene (i.e. p-actin), expression values were calculated by the 
2-(aaci) as described elsewhere (Livak and Schmittgen, 2001). 
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2.6 Statistical analysis of real-time RT-PCR results 
One way ANOVA using turkey test was used to analyze the results and 
determined if there was a differential expression of particular gene in different 
DCIS grades. 
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2.7 Immunohistological analysis of the expression pattern of the potential 
DCIS marker 
To examine the protein expression pattern of the potential DCIS marker, blocks 
of FFPE tissues containing DCIS mentioned in Seclion2.2 were used in the 
immunohistological analysis. 
First, the slides were deparaffinized and rehydrated with xylene and alcohol and 
was subjected to antigen retrieval with microwave in EDTA for 15min. After 
cooling for 30min, slides were preincubated in a 0.3% hydrogen 
peroxide/melhanol buffer for 15min to block the endogenous peroxidase. Then 
the slides were treated with 0.3% bovine serum albumin/Tris-buffered saline 
blocking solutions for 30min, to create a favorable condition for secondary 
antibody binding and reduce irrelevant binding, before the application of the 
primary antibody. In this study, two antibodies were used: Erbb2 (membrane 
staining) and ETV6 (nuclear staining). 
For the use of Erbb-2 (DAKO #a0485, Denmark, dilution 1:300), a rabbit 
anti-human polyclonal antibody, as primary antibody, it was incubated at room 
temperature overnight and were detected using biolinylated swine anti-rabbit 
polyclonal antibody F0054 (DAKO, Denmark, dilution 1:200) for 30 minutes. 
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For the use of ETV6 (abeam #ab54705. United Kingdom, dilution 1:300), a 
mouse anti-human monoclonal antibody, as primary antibody, it was incubated 
at room temperature overnight and were detected using biotinylated rabbit 
anti-mouse polyclonal antibody E0413 (DAKO, Denmark, dilution 1:200) as 
secondary antibody for 30 minutes. 
After the application of the primary and secondary antibodies, horseradish 
peroxidase-labelled polymer from Dako Envision was used to amplify the signal. 
Signal was finally developed and visualized with 3,3'-diaminobenzidine and 
counterstained with diaminobenzidine followed by haematoxylin. 
After the counterstaining, all sections were dehydrated in alcohol and xylene 
and were mounted. 
4 3 
2.8 Evaluation of immunohistological staining 
For evaluation of both Erbb-2 and ETV expression, all slides were examined by 
light microscopy. 
Cells showing a membrane staining pattern were evaluated for its signal 
intensity, ranging from 0 (no signal) to 3 (very strong signal), in both Erbb-2 
and ETV treated slides. 
2.9 Statistical analysis of immunohistological results 
Chi-square test was used for the statistical analysis of the previous 
immunohistochemical results. 
For chi-square test, it was used to evaluate if the observed different signal 
intensities in different DCIS grades had any significant different with the 
expected observation. Significance was considered to be P less than 0.05. 
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Chapter 3: Analysis of Expression Pattern of Potential DCIS Markers 
3.1 Construction of DCIS data base from FFPE tissue 
A total of 213 samples were collected from Kwong Wah Hospital and the Prince 
of Wales hospital, with a contribution of 118 and 95 samples respectively. 
According to Van Nuy grading system, among these cases, low grade DCIS 
occurred in 72 cases (33.8%), intermediate grade in 61 cases (28.6%) and high 
grade in 80 cases (37.6%). The mean age of patients was 53, with age ranged 
from 30 to 90. 
In our samples collected, they are removed from several procedures including 
biopsy (i.e. core needle biopsy), excision (i.e. wide local excision) and 
mastectomy. 
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3.2 Analysis of expression of potential DCIS markers from PCR 
3.2.1 First strand cDNA synthesis and PCR screening 
After the successful extraction of RNA from all the samples, reverse 
transcription was carried out according to the protocol. 
For cDNA quality, it was checked by running PCR with P-actin primers which 
is the house keeping gene. From the PCR products resolved on the 2%gel, sharp 
band of p-actin was being seen. Thus cDNA quality was assured for further 
studies. 
• • • • • • • I bp 
Fig. 3.1 Gel photo of B-actin check on first strand cDN A (Primers: F: 5，-CTGGCACC 
CAGCACAATG-3，and R: 5，-GCCGATCCACACGGAGTACT-3，. Since the primers 
flanked the exon region, cDNA quality was assured for further studies. The above were 
selected cases in 2004. 
cDNA were successfully reversed transcribed from all the samples, and with the 
synthesized cDNA as template, PCR for each pair of primer stated in Table 2.1 
was run. Then the PCR products were resolved on 2% agarose gel for detection 
of the presence and absence of bands. 
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Below were the representative gel photos for the 46 primers of 2004 cases. 
G G C X bp 
Fig.3.2 Gel photo of G G C X on first strand cDNA. G G C X 
(gam ma-glutamyl carboxylase) locates on chromosome 2 and its protein 
encoded functions as Vitamin K-dependent clotting factor, deficiency of 
it causes multiple coagulation factor deficiency. 
VAMP 8 bp 
141 
Fig.3.3 Gel photo of VAMPS on first strand cDNA. VAMPS 
(vesicle-associated membrane protein) locates on chromosome 2 and 
functions as vesicles transporter. It plays a role in regulated enzyme 
secretion in pancreatic acinar cells, involved in the abscission of the 
midbody during cell division, which leads to completely separate 
daughter cells. 
CKLFSF 8 
^^^BKB^M^^^^JLjl^.^ I w B 
Fig.3.4 Gel photo of CKLFSF 8 on first strand cDNA. C K L F S F 8 
(CKLF-!ike M A R V E L transmembrane domain containing 8) locates on 
chromosome 3 and inhibits cell proliferation and expression of E G F R of 
tumor cells. It was seen to promote cell proliferation upon knockdown of 
CKLFSF8 by siRNA. 
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TBP BP 
Fig.3.5 Gel photo of TBP on first strand cDNA. TBP (TATA box-binding 
protein-like protein 1) locates on chromosome 4 and its protein 
encoded acts as a transcription regulator. It encodes a protein that 
substitutes for some promoters that are not recognized by transcription 
factor I ID. It is essential for spermiogenesis and important in 
expression of developmentally regulated genes. 
Fig3.6 Gel photo of ANLN on first strand cDNA. ANLN (anillin) locates 
on chromosome 7 and its protein encoded is essential for the structural 
integrity of the cleavage furrow and for completion of cleavage furrow 
ingression. It is ssentiai for cytokinesis. Up-regulation of ANLN is a 
common feature of the carcinogenetic process in lung tissues. 
TOX bp 
H H H H ^ H H I H ^ H H 
Fig.3.7 Gel photo of T O X on first strand cDNA. T O X (thymus high 
mobility group box protein) locates on chromosome 8 and encodes a 
protein facilitates binding of DNA in a sequence-independent but 
structure-dependent manner. It is also prospoed to play a role in 
regulating T-cell development. 
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B i G i bp 
m ^ H m j B B I ^ H B B i l H Q C Z S Q I 92 
Fig.3.8 Gel photo of B IG I on first strand cDNA. B I G I (brefeidin 
A-inhibited guanine nucleotide-exchange protein 1) locates on 
chromosome 8 and encodes a protein promotes guanine-nucleotide 
exchange on A R F l and ARF3. It also promotes the activation of 
ARF1/ARF3 through replacement of G D P with GTP. 
P X M P 3 bp 
Fig.3.9 Gel photo of PXMP3 on first strand cDNA. P X M P 3 
(peroxisomal membrane protein 3) locates on chromosome 8 and 
encodes an integral peroxisomal membrane protein required for 
peroxisome biogenesis. Mutations in this gene result in one form of 
Zellweger syndrome and infantile Refsum disease. 
K iAA n ^ ^ m m m i i i m i ^ ^ ^ m i m i i m bp 
0196 m m m m m o ^ m m m B H 
Fig.3.10 Gel photo of K1AA0196 on first strand cDNA. KIAA0196 
locates on chromosome 8 and is an uncharacterized protein of which 
the expression was significantly higher in tumors with the gene 
amplification than in those without it. This suggested that KIAA0196 is 
a putative target genes for the common amplification of 8q23-24 
prostate cancers. 
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Fig.3.11 Gel photo of Z H X l on first strand cDNA. Z H X l (zinc fingers 
and homeoboxes 1) locates on chromosome 8 and functions as 
transcriptional repressors. This is achieved by interacting with the A 
subunit of nuclear factor-Y (NF-YA) and contain two C2H2-type zinc 
fingers and five homeobox DNA-binding domains. 
CD164 bp 
L 1 159 
Fig.3.12 Gel photo of CD164L1 on first strand cDNA. CD164L1 locates 
on chromosome 11 and is proposed to play a role in tumor 
angiogenesis. It is found expressed in tumor endothelial cells but absent 
or barely detectable in normal endothelial cells. 
SLC29 bp 
A2 H H ^ H H H I ^ ^ B H H ' ' ' 
Fig.3.13 Gel photo of SLC29A2 on first strand cDNA. SLC29A2 locates on 
chromosome 11 and encodes a ucleoside transporter protein. It remained as 
an uncharacterized protein. 
Fig.3.I4 Gel photo of U V R A G on first strand cDNA. UVRAG (UV 
radiation resistance-associated gene protein) locates on chromosome 11 
and showed a proliferation suppression. Chromosomal aberrations 
involving this gene are associated with left-right axis malformation and 
mutations in this gene have been associated with colon cancer. 
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w N T i i 
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Fig.3.15 Gel photo of W N T l l on first strand cDNA. W N T l l locates on 
chromosome 11 and is a putative signaling molecule. It is a ligand for 
members of the frizzled family of seven transmembrane receptors which 
affects the development of discrete regions of tissues. 
P A K l bp 
Fig.3.16 Gel photo of PAK l on first strand cDNA. ( PAK l ) 
Serine/tbreonine-protein kinase PAK 1 locates on chromosome 11 and is 
a stress fibres dissolution. Its activity is inhibited in cells undergoing 
apoptosis, potentially due to binding of CDC2L1 and CDC2L2 
ETV6a bp 
104 
Fig.3.17 Gel photo of ETV6a on first strand cDNA. ETV6 (Transcription 
factor ETV6) locates on chromosome 12 and is s transcriptional 
repressor. It can form homodimers or heterodimers with TEL2 or FLU. 
Exon 4 was being flanked. 
ETV6b j ^ m n i i i i i i i i n ^ j ^ i ^ ^ ^ ^ i i m m i i ^ i 二 
Fig.3.18 Gel photo of ETV6b on first strand cDNA. ETV6 (Transcription 
factor ETV6) locates on chromosome 12 and is s transcriptional 
repressor. It can form homodimers or heterodimers with TEL2 or FLU. 
Exon 3, 4 was being flanked. 
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H2AFJa bp 
Fig.3.19 Gel photo of H2AFJa on first strand cDNA. H2AFJ (H2A 
histone family, member J ) locates on chromosome 12 and encodes a 
histone octamer. The protein is an uncharacterized but quantitative 
RT-PCR indicated that the gene is regulated in a 
replication-independent manner. Exon 1 was being flanked. 
H2AFJb bp 
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Fig.3.20 Gel photo of H2AFJb on first strand cDNA. H2AFJ (H2A 
histone family, member J ) locates on chromosome 12 and encodes a 
histone octamer. The protein is an uncharacterized but quantitative 
RT-PCR indicated that the gene is regulated in a 
replication-independent manner. Exon 1 was being flanked. 
H2AFJC p 
586 
Fig.3.21 Gel photo of H2AFJc on first strand cDNA. H2AFJ (H2A 
histone family, member J ) locates on chromosome 12 and encodes a 
histone octamer. The protein is an uncharacterized but quantitative 
RT-PCR indicated that the gene is regulated in a 
replication-independent manner. Exon 1 was being flanked. 
Fig.3.22 Gel photo of EPS8a on first strand cDNA. EPS8 (epidermal 
growth factor receptor pathway substrate 8) locates on chromosome 12 
and encodes a cell growth inhibitor. It may play a role in regulation of 
EGF-induced Erk pathway activation and involved in cytoskeletal 
reorganization and E G F R signaling. Exons 19, 20 and 21 were flanked. 
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Fig.3.23 Gel photo of EPS8b on first strand cDNA. EPS8(epidermal 
growth factor receptor pathway substrate 8) locates on chromosome 12 
and encodes a cell growth inhibitor. It may play a role in regulation of 
EGF-induced Erk pathway activation and involved in cytoskeletal 
reorganization and E G F R signaling. Exons 18 and 19 were flanked. 
KRAS2a P 
H B B B B Z B S E B S ^ B Q H 89 
Fig.3.24 Gel photo of KRAS2a on first strand cDNA. KRAS2 (v-Ki-ras2 
Kirsten rat sarcoma viral oncogene homolog) locates on chromosome 
12 and protein encoded binds GDP/GTP and possess intrinsic GTPase 
activity. Defects in K R A S sometimes cause juvenile myelomonocytic 
leukemia ( J M M L ) while KRAS mutations are involved in cancer 
development. Exon 3 was flanked. 
KRAS2b bp 
Fig.3.25 Gel photo of KRAS2b on first strand cDNA. KRAS2 (v-Ki-ras2 
Kirsten rat sarcoma viral oncogene homolog) locates on chromosome 
12 and protein encoded binds GDP/GTP and possess intrinsic GTPase 
activity. Defects in K R A S sometimes cause juvenile myelomonocytic 
leukemia ( J M M L ) while KRAS mutations are involved in cancer 
deveJopment Exons 2 and 3 was flanked. 
s u 腿 86 
Fig.3.26 Gel photo of SURB7 on first strand cDNA. SURB7 (supressor 
of R N A polymerase B) locates on chromosome 12 and encodes a 
transcription regulator. It represses activation of transcription by 
RNAP I l . Exon 4 was flanked. 
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RAP IB bp 
Fig.3.27 Gel photo of R A P I B on first strand cDNA. R A P I B (Ras-related 
protein Rap-lb) locates on chromosome 12 and encodes an isoform of 
R a p l , a member of the Ras superfamily of monomeric GTPases,closely 
related to Ras. It is involved in the regulation of integrin-mediated cell 
adhesion. Exon 8 was flanked. 
DMN H H ^ H I H H I i i i ^ H I H I ^^ 
Fig.3.28 Gel photo of D M N on first strand cDNA. D M N (Desmuslin) 
locates on chromosome 15 and encodes is a type-VI intermediate filament 
which may function as a mechanical support to the muscle fibers. It 
could induce liver injury and stimulates proliferation and reduces 
apoptosis of hepatocytes, and also up-regulates the transcription of 
various growth factors upon anti-TGF-beta molecular intervention. Exon 
4 was flanked. 
H A G H 
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Fig.3.29 Gel photo of H A G H on first strand cDNA. H A G H 
(Hydroxyacylglutathione hydrolase) locates on chromosome 16 amd 
catalyzes the hydrolysis of S-D-lactoyl-glutathione to form glutathione 
and D-lactic acid. Exon 10 was flanked. 
E4F1 bp 
Fig.3.30 Gel photo of E4F1 on first strand cDNA. E4F1 (E l A-regulated 
cellular transcription factor) locates on chromosome 16 encodes a 
protein required for adenovirus replication. Its transcription factor 
binding site and interactions of some other DNA elements with 
trans-acting factors are likely to modulate the expression of the B R C A l 
gene which is a breast cancer marker. Exon 14 was flanked. 
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Fig.3.31 Gel photo of T IAF l on first strand cDNA. T IAF l 
(TGFBl-induced anti-apoptotic factor 1) locates on chromosome 17 
and inhibits the cytotoxic effects of TNF-alpha and overexpressed TNF 
receptor adapters. T IAF l and p53 functionally interact in regulating 
apoptosis, and T IAF l is likely to participate in the nuclear 
translocation of activated p53. Exon 1 was flanked. 
Fig.3.32 Gel photo of CDK5R1 on first strand cDNA. CDK5R1 
(Cyclin-dependent kinase 5 activator 1) locates on chromosome 17 and 
the protein encoded activates p35 while the p35/CDK5 is required for 
neurite outgrowth and cortical lamination. Cleavage of p35 to p25 (i.e. 
p25/Cdk5 complex) induces cytoskeletal disruption, morphological 
degeneration and apoptosis. Exon 2 was flanked. 
Fig.3.33 Gel photo of NAP4 on first strand cDNA. NAP4 
(Neutrophil-activating protein 4) locates on chromosome 17 and 
induces chemotaxis of neutrophils. It showed also binding to activated 
EGF receptor. Exon 1 was flanked. 
MLLT6 ^ u m n i i i m i i i i i i n 二 
Fig.3.34 Gel photo of MLLT6 on first strand cDNA. MLLT6 
(myeloid/lymphoid or mixed-lineage leukemia translocated to, 6) 
locates on chromosome 17. A chromosomal aberration involving 
MLLT6 is associated with acute leukemias. Exon 10 was flanked. 
5 5 
Erbb2 
Fig.3.35 Gel photo of Erbb2 on first strand cDNA. Erbb2 (v-erb-b2 
erythroblastic leukemia viral oncogene homolog 2) locates on 
chromosome 17 and encodes a protein involving mitogen activated 
protein kinase and phosphatidylinositol-3 kinase. Erbb2 overexpression 
associates to the malignant phenotype. The role of this receptor in 
controlling celJ fate can also lead to differentiation and apoptosis. It is a 
known marker for brast cancer. Exon 21 was flanked. 
Fig.3.36 Gel photo of N G F R on first strand cDNA. N G F R (nerve growth 
factor receptorO locates on chromosome 17 and its expression may be 
involved in the perineural invasion of pancreatic cancer cells, and the 
mechanism might be through mediating the chemoattraction of cancer 
cells for neural tissues. Exon 6 was flanked. 
ITGB4 bp 
Fig.3.37 Gel photo of ITGB4 on first strand cDNA. UTGB4 (Integrin 
beta-4) locates on chromosome 17 and protein encoded is a receptor for 
laminin. It plays a critical structural role in the hemidesmosome of 
epithelial cells. Defects in ITGB4 are a cause of generalized atrophic 
benign epidermolysis bullosa (GABEB) , which is characterized by 
life-long blistering of the skin, associated with hair and tooth 
abnormalities. Exon 36 was flanked. 
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Fig.3.38 Gel photo of PVR on first strand cDNA. PVR (Poliovirus 
receptor) locates on chromosome 19 and protein encoded mediates NK 
cell adhesion plays a role in mediating tumor cell invasion and 
migration. Exon 8 was flanked. 
CEBPB bp 
Fig.3.39 Gel photo of CEBPB on first strand cDNA. CEBPP 
(CCAAT/enhancer binding protein) locates on chromosome 20 and 
protein encoded binds DNA as a dimer and can form stable 
heterodimers with C/EBP alpha, delta and gamma. It is also an 
important transcriptional activator in the regulation of genes involved 
in immune and inflammatory responses. Exon 1 was flanked. 
BCAS4 bp 
Fig.3.40 Gel photo of BCAS4 on first strand cDNA. BCAS4 (Breast 
carcinoma amplified sequence 4) locates on chromosome 20. A 
chromosomal aberration involving BCAS4 may be a cause of breast 




Fig.3.41 Gel photo of ADNP on first strand cDNA. ADNP 
(activity-dependent neuroprotector) locates on chromosome 20 and 
encodes a potential transcription factor. It mediates some of the 
neuroprotective peptide VIP-associated effects involving normal 
growth and cancer proliferation and shows strong increase of 
expression in colon and breast cancer tissues. Exon 5 was flanked. 
AIRE bp 
Fig.3.42 Gel photo of A I R E on first strand cDNA. A I R E (Autoimmune 
regulator) locates on chromosome 21 and encodes a transcriptional 
regulator protein that binds to DNA as dimer and tetramer. Defects in 
A I R E are a cause of autoimmune poly-endocrinopathy candidiasis 
ectodermal dystrophy (APECED) , of which a high proportion of 
patients develop squamous cell carcinoma of the oral mucosa. Exon 
15 was flanked. 
Fig.3.43 Gel photo of COL6A1 on first strand cDNA. COL6A1 
(Collagen alpha-l(VI) chain) locates on chromosome 21 and encodes a 
cell-binding protein maintaining the integrity of various tissues. 
Defects in COL6A1 are a cause of Bethlem myopathy which is a rare 
autosomal dominant proximal myopathy characterized by early 
childhood onset. Exon 35 was flanked. 
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Fig.3.44 Gel photo of M L C l on first strand cDNA. M L C l 
(megalencephalic leukoencephalopathy with subcortical cysts 1) locates 
on chromosome 22 and encodes a putative transporter which may act as 
a non-selective neuronal cation channel. Defects in M L C l causes 
megalencephalic leukoencephalopathy with subcortical cysts (MLC) , the 
brain appears swollen with diffuse white-matter abnormalities and the 
invariable presence of subcortical cysts. Exon 13 was flanked. 
TUBGCP6 bp 
Fig.3.45 Gel photo of TUBGCP6 on first strand cDNA. TUBGCP6 
(Camma-tubul in complex component 6) locates on chromosome 22 and 
encodes a gamma-tubulin complex is necessary for microtubule 
nucleation at the centrosome. Exon 23 was flanked. 
Fig.3.46 Gel photo of HDAC IO on first strand cDNA. HDACIO (Histone 
deacetylase 10) locates on chromosome 22 and is responsible for the 
deacetylation of lysine residues on the N-terminal part of the core 
histones. H D A C could be inhibited by CRA-024781, resulting in an 
inhibition of tumor cell growth and the induction of apoptosis. Exon 13 
was flanked. 
^ • • • • • ^ • • • { ^ • H bp 
Fig.3.47 Gel photo of RPL39 on first strand cDNA. RPL39 (60S 
nbosomal protein L39) locates on chromosome X. It showed to be 
ribosomal biogenesis and translational control related and suggested to 
participate in mammary gland tumorigenesis by promoting genetic 
instability and cell proliferation. Exon 2 was flanked. 
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3.2.2 Statistical analysis of PCR results 
The data were then input to the SPSS for statistical analysis. To allow a 
preliminary but comprehensive screening, several statistical models were 
included in order to choose a candidate gene with potential as a biomarker of 
DCIS progression. They were 
i. Chi-square 
ii. Logistic regression 
3.2.3.1 Chi-square tests 
In the study, chi-square was chosen as one of the preliminary analyses was 
because of its ability to observe the actual gene expression to theoretical gene 
expression in samples of different DCIS grades. Chi-square was run to analyze 
the gene expression on tumor samples and results were shown in the following 
table. 
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Tab le s h o w i n g the Ch i-squa re test results acco rd i ng to the gene expression pa t te rn 
Low (% out of 65 High (% out of 148 
Gene Name Significance 
low grade cases) high grade cases) 
1 GGCX 4 (6.15) 29(19.6) 0.326 
2 VAMPS 7(10.8) 23(15.5) 0.380 
3 CKLFSF8 20 (55.4) 67(45.3) 0.372 
4 TBP 14 (21.5) 32(23.0) 0.530 
5 ANLN 11(16.9) 34(21.0) 0.526 
6 TOX 31(47.7) 76(51.4) 0.230 
7 BIGl 43(66.2) 85(57.4) 0.164 
8 PXMP3 16(024.6) 57(38.5) 0.407 
9 KIAA()196 43(66.2) 105(71.0) 0.544 
10 ZHXl 32(49.2) 70(47.3) 0.347 
11 CD164L1 25(38.5) 50(33.8) 0.489 
12 SLC29A2 32(49.2) 67(45.3) 0.215 
13 UVRAG 22(33.8) 57(38.5) 0.222 
14 WNTll 13(20.0) 27(18.2) 0.548 
15 PAKl 14(21.5) 38(15.7) 0.097 
16 ETV6a 19(29.2) 36(24.3) 0.009 
17 ETV6b 20(30.8) 49(33.1) 0.007 
18 H2AFJa 29(44.6) 61(41.2) 0.005 
19 H2AFJb 29(44.6) 55(37.2) 0.026 
20 H2AFJC 2(3.1) 4(2.7) 0.449 
21 EPS8a 20(30.8) 43(29.1) 0.128 
22 EPS8b 9(13.8) 21(14.2) 0.008 
23 KRAS2a 54(83.1) 118(79.7) 0.203 
24 KRAS2b 13(20.0) 25(16.9) 0.268 
25 SURB7 47(72.3) 92(62.2) 0.177 
26 RAP IB 49(75.4) 103(69.6) 0.395 
27 DMN 9(13.8) 38(25.7) 0.269 
28 HAGH 18(27.7) 60(40.5) 0.087 
29 E4F1 31(47.7) 83(56.1) 0.520 
30 TIAFl 11(16.9) 35(23.6) 0.029 
31 CDK5R1 23(35.4) 60(40.5) 0.491 
32 NAP4 57.7) 29(19.6) 0.204 
33 MLLT6 0(0.0) ()(().()) N/A 
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34 Erbb2 50(76.9) 44(29.0) 0.041 
35 NGFR 13(20.0) 32(21.6) 0.076 
36 ITGB4 7(10.8) 31(20.9) 0.135 
37 PVR 11(16.9) 43(29.1) 0.146 
38 CEBPB 20(30.8) 52(35.1) 0.110 
39 BCAS4 0(0.0) 9(6.1) 0.436 
40 ADNP 9(13.8) 34(23.0) 0.109 
41 AIRE 7(10.8) 30(20.3) 0.268 
42 C0L6A1 43(66.2) 114(77.0) 0.195 
43 MLC l 2(3.1) 11(7.4) 0.424 
44 TUBGCP6 5(7.7) 16(10.8) 0.520 
45 HDACIO 4(6.2) 32(21.6) 0.464 
46 RPL39 0(0.0) 4(2.7) 0.215 
Table 3.2 Table showing the chi-square test results according to the gene expression pattern shown in 
PCR. Samples were grouped according to their respective DCIS grades for the analysis and the 
respective % were shown also. Results were significant at 0.05 level. 
A number of genes showed significance results in chi-square test, they were 
GGCX(p=0.008), ETV6a(p=0.035), ETV6b(p=().()02) H2AFJa(p=0.005), 
H2AFJb(p=0.023) EPS8(p=0..003), TIAF1 (p=0.003), ITGB4(p=0.012), 
PVR(p=0.008)，ADNP(p=0.011), COL6Al(p=0.039) and HDAC10(p=0.039). 
Since the chi-square test was only a preliminary screening looking for 
significant difference between observed and expected expression on PCR results, 
all the 46 genes were subjected to further statistical analysis so as to look for the 
candidate genes which had the greatest potential to be the DCIS marker. 
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3.2.3.2 Logistic regression 
For logistic regression, it is used for the prediction of the probability of a 
particular gene expression in certain DCIS grade. 
According to the logistic regression model, ETV6 and Erbb2 showed a 
differential expression in different DCIS stages. These two genes showed also 
significant results of tumor tissue from the chi-square test. 
According to the equation mentioned 2.4.2, two significant statistical models 
were constructed using expression pattern of ETV6 and Erbb2. The first one 
established with the expression pattern of ETV6 was: 
I = 2.339-0.339*ETV6a expression (p=0.033) 
Upon transformation of the value of z using 
1/(1+ e ' ) 
The probability of the DCIS grade accurately diagnosed could be revealed. For 
example, a patient with high grade DCIS (Grade II or III), with the presence of 
ETV6a bands in PCR, the z value could be calculated as follow (taking "1" as 
positive and "0" as negative): 




Upon transformation with the equation 1/(1+ e"^), the probability of an accurate 
diagnosed grade could be calculated as 
=1/(1+e-丨 355) 
=0.79 
To conclude, this patient has a 79% chance with high grade DCIS. 
Another model with a greater significance (p=0.031) was established with the 
expression pattern of both ETV6 and Erbb2: 
Z = 1.522-0.259*ETV6a expression + 0.n5*Erbb2 expression (p=0.031) 
Upon transformation of the value ofz using the equation 
1/(1+ e-z) 
The probability of the DCIS grade accurately diagnosed could further be 
calculated with significance. An example illustrating this is as follow: 
For a patient with high grade DCIS and indicating a presence of ETV6a bands 
and presence of Erbb2 bands in PCR, the z value could be calculated as follow 
(taking "1" as positive and "0" as negative): 
z = 2.258-0.259*l+0.175*l 
=1.99 
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Upon transformation with the equation 1/(1+ e" '^), the probability of an accurate 
diagnosed grade could be calculated as 
=0.88 
To conclude, this patient has a 88% chance with high grade DCIS. 
With the application of the above calculations, these could be served as a 
reference for pathologists for the suggestion of treatment for the DCIS patient. 
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3.3 Conclusion 
RNA extraction from FFPE samples was successfully performed on the tumor 
tissues and the adjacent normal tissues. Reverse transcription was taken place 
and cDNA was synthesized. Then PCR using the newly synthesized cDNA as 
templates was run with the primers of the 46 pairs of potential DCIS markers. 
Upon resolve of the PCR products on the 2% agarose gel, the expression pattern 
of each gene on the samples was observed and any differential expression was 
analyzed using various statistical models. 
Preliminary screening of potential genes for further studies was performed with 
various statistical tests. First chi-square was chosen to lest if there were any 
potential markers showing a significant difference between observed and 
expected expression on DCIS tumor or adjacent normal samples. Potential 
candidate genes were subjected further to binary logistic regression and ordinal 
regression to test for significant relationship between the disease and gene 
expression. 
Two potential genes showed differential expression in the tumor tissues in the 
three statistical analysis, they were ETV6 and Erbb2. These mentioned genes 
were selected for further studies to look into their relationship with the DCIS in 
tumor tissues. 
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Chapter 4 Real-time RT-PCR analysis of expression of selected potential 
DCIS markers 
After the initial PCR screening and statistical analysis, ETV6 and Erbb2 showed 
significant expression in tumor tissues of different DCIS grades. They were then 
subjected to more sensitive detection of the specific gene expression performed 
by real-time RT-PCR and to quantify the level of their expression in different 
DCIS tissues. 
The primer sets for the ETV6 and Erbb2 were the same as the ones for the PCR 
screening as mentioned in Table 2.1 in Section 2.3, and the primer set for 
p-actin was the same as the one used in the (3-actin check for first strand cDNA 
synthesis. All the RNA samples extracted were subjected to real-time PCR 
analysis to ensure they were genomic contamination free. 
From the results, all samples showed no detectable Ct values and proved thai the 
RNA templates were free of genomic contamination. The sequences were 






















































































































































































































































































































































































































4.1 Expression of ETV6 in tumor and adjacent normal tissues in different DCIS 
grades 
Level of ETV6 expression among different 
grades of DCIS in tumor and adjacent 
normal tissues 
> 5 1 
O 
o -w 4 " i 
"I 2 ^ i - , 
(/} o 
2 ^ 3 _ 
X . 
® d o -
0 Z 2 _ _ 
^ 1 
m ^ I ； ~ ( i 1 1 
A — II I I ^ n n F 1 n r n 
0 
Control Adj I Adj ！I Adj III Tumor I Tumor II Tumor Hi 
DCIS grades 
Fig. 4.1 Graph showing ETV6 expression among different DC IS grades in tumor and adjacent 
normal tissues 
According to the positive results as shown from PCR, 55 samples from the tumor 
cases and 42 samples from the adjacent normal cases were selected for real-time 
studies. 
From the graph, ETV6 showed a general higher expression in the adjacent normal 
tissue than in the tumor tissue. Also, the expression of ETV6 showed an increase in 
expression with the increase of DCIS grades in adjacent normal tissues, but an 
opposite trend in the tumor tissues. 
For its expression level in tumor tissue, it was similar to that in the control. While in 
the intermediate and high grade tumor tissues, they showed an expression lower than 
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the control. 
In the adjacent normal tissue, the expression of ETV6 was different when comparing 
to the tumor tissues. For low grade DCIS, the expression of ETV6 was similar in the 
adjacent and tumor tissue. However, it had a higher expression in the adjacent normal 
tissues than in the tumor tissues in the intermediate and high grade DCIS. The extent 
of difference high grade DCIS was larger than in the intermediate. 
In the previous statistical analysis, ETV6 showed a significant difference in the 
expression pattern in the tumor tissue. While from the real-time PCR results, the 
difference in the expression of ETV6 in each DCIS grade was of a smaller extent than 
in the adjacent normal tissue. 
The reason encountering that might be the statistical analysis based only on the 
difference in occurrence of ETV6 expression in different grades of DCIS, while the 
intensity of the PCR bands was not among the parameters to be considered. 
Interestingly, ETV6 showed an increase expression with the increase of DCIS grades, 
which was not expected from the previous statistical analysis. 
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4.2 Expression of Erbb2 in tumor and adjacent normal tissues in different DCIS 
grades 
Level of Erbb2 expression among 
different grades of DCIS in tumor and 
adjacent normal tissues 
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Fig. 4.2 Graph showing Erbb2 expression among different DCIS grades in tumor and 
adjacent normal tissues 
According to the positive results as shown from PCR, 94 samples from the tumor 
cases and 55 samples from the adjacent normal cases were selected for real-time 
studies. 
From the real-time PCR results, Erbb2 showed a similar trend of increase in both the 
adjacent and tumor tissues. For in both the adjacent normal and tumor tissues , upon 
comparing with the control, the expression of Erbb2 in low grade DCIS in both the 
adjacent normal and tumor tissues were almost doubled; then its expression in the 
intermediate grade DCIS almost doubled the low grade DCIS. Its expression was the 
7 1 
highest in the high grade DCIS. 
However, despite the similar in trend, statistical analysis showed only significance 
Erbb2 expression in tumor tissues. This might again due to the intensity of the PCR 
bands not among the parameters being considered in the statistical analysis. 
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Chapter 5 Analysis of Protein Expression Pattern of Potential DCIS Markers 
To study the protein expression pattern of potential DCIS markers, IHC study were 
chosen for further analysis. 
5.1 Chi square test 
Chi-square test was used to further analysis the protein expression of ETV6 and 
Erbb2 in different DCIS grades. 
The cases were divided into two groups for comparison, namely "Low Grade DCIS" 
and "High Grade DCIS", the former one representing Grade I DCIS while the latter 
one representing Grade II and Grade III DCIS cases. Then the intensity of IHC results 
were divided into two groups, namely "Low intensity” and “High intensity", the 
former representing the IHC signals scored 0 and 1 while the latter representing IHC 
signals scored 2 and 3. 
The cases used for the IHC study was based on the positive results showed in PCR. 
For ETV6, there were 55 and 42 cases for tumor and adjacent normal samples 
respectively; while for Erbb2, there were 94 and 55 cases for tumor and adjacent 
normal samples respectively. 
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5.1.1 Immunohistochemical study of ETV6 in tumor and adjacent normal DCIS 
tissues 
From the statistical chi-square test after the PCR screening, ETV6 showed a 
differential expression pattern in tumor tissue with the observation of nuclear staining. 
In the real-time PCR, high ETV6 expression was observed in adjacent normal tissues, 
while high grade tumor tissue showed an expression similar to the control. 
With the application of immunohistochemical analysis in both adjacent and tumor 
tissue, it might provide a glimpse in the translation of this potential DCIS marker and 
the relationship in DCIS progression. 
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Fig. 5.1 I H C image of ETV6 in tumor tissues (lOOX). Some representative signals given out 
by the ETV6 nuclear staining in tumor tissues were indicated in the box (T). 
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Fig. 5.2 I H C image of ETV6 in adjacent normal tissues (lOOX). Some representative signals 
given out by the ETV6 nuclear staining in adjacent normal tissues were indicated in the box 
(A). 
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For the tumor samples, there were 55 cases selected for the IHC study, including 19 
low grade and 36 high grade DCIS cases. 
For the 19 high grade DCIS cases there were 15 cases showed low signal intensity 
while 6 showed high signal intensity. For the 36 high grade DCIS cases, there were 17 
cases showed low signal intensity while 19 showed high signal intensity. From the 
chi-square test, the above data gave a significant results at p二0.023 (<0.05). 
For the adjacent normal samples, there were 42 cases selected for the IHC study, 
including 15 low grade and 27 high grade DCIS cases. 
For the low grade DCIS cases, 6 and 9 of them were of low and high signal intensity 
respectively. For the high grade DCIS cases, 6 showed low signal intensity and 21 
showed high signal intensity. The above data gave a significance of p=0.222 (>0.05). 
The chi-square test showed ETV6 protein expression had a significant difference in 
observation than expected in tumor but not in adjacent normal tissues. 
Tumor Adjacent Normal 
Low Grade High Grade Low Grade High Grade 
Low I H C intensity 15 17 6 6 
High I H C intensity 4 19 9 21 
Total 19 36 15 27 
Significance p=0.023 (<0.05) |)=0.222 (>0.05) 
Tab le 5a. Tab le s h o w i n g the s u m m a r y o f chi-square test for E T V 6 I H C results 
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5.1.2 Immunohistochemical study of Erbb2 in tumor and adjacent normal DCIS 
tissues 
In the PCR screening, Erbb2 showed a differential expression pattern while in the 
real-time PCR, Erbb2 expression increased with the DCIS grades and similar pattern 
was observed in both adjacent normal tissues and tumor tissues with the observation 
of membrane staining. 
In sight to elucidate the difference of Erbb2 protein expression in different DCIS 
grades, immunohistochemical analysis was performed in both adjacent and tumor 
tissue with similar setup as in section 5.1.1. 
Since Erbb2 is a well-known marker for breast cancer, results from this section 
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Fig. 5.3 I H C image of Erbb2 in tuiTior(T) and adjacent normal (A) tissues (lOOX). The 
brown areas represented the signal given our by the Erbb2 membrane staining. 
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According to the positive results from PCR, 94 tumor cases and 55 adjacent normal 
cases were selected for IHC analysis. 
For tumor cases, 50 of them were of low DCIS grade while 44 of them were of high 
DCIS grade. Then in the low grade DCIS cases, 30 of them gave low signal intensity 
and 20 of them gave high signal intensity. While for the high grade DCIS, 17 of them 
gave low signal intensity and 27 of them gave high signal intensity. 
For the adjacent normal cases, there were 18 low grade and 37 high grade DCIS cases. 
In the low grade DCIS cases, 15 and 3 cases showed low and high signal intensity 
respectively. In the high grade DCIS cases, 34 and 3 cases showed low and high 
signal intensity respectively. 
The chi-square test gave a significance of p=0.012 (<0.05) in tumor samples and 
p=0.339(>0.05) in adjacent normal samples. This indicated that there was a significant 
difference in observation of Erbb2 protein expression level than expected in tumor 
tissues but not in adjacent normal tissues. 
Tumor Adjacent Normal 
Low Grade High Grade Low Grade High Grade 
Low I H C intensity 30 17 15 34 
High IHC intensity 20 27 3 3 
Total 50 44 18 37 
Significance p=0.012 (<0.05) 丨)=0.339 (>0.05) 
Table 5b. Table s how i ng the s u m m a r y of chi-square test for E r bb2 I H C results 
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5.2 Conclusion 
Both ETV6 and Erbb2 IHC analysis in DCIS tumor tissues showed significant results 
in the chi-square test, this further indicated the potential of these candidate genes as 
prognostic DCIS markers. 
8 0 
Chapter 6 General discussion 
DCIS was a type of pre-invasive breast cancer and had the potential to develop into 
invasive diseases. While for the VNPI of DCIS grading, the biological potential in its 
progression to invasive cancer was not indicated, but giving only prediction to local 
recurrence of breast cancer. Therefore, potential markers for DCIS were screened for 
in the project so as to gain insight in biological potential of DCIS progression. 
Upon the selection of DCIS cases, PCR screening was carried out and ETV6 and 
Erbb2 showed significant difference in expression pattern after the chi-square test and 
binary logistic. They were selected for further real time PCR and IHC analysis. 
In the real time PCR, ETV6 showed an increase in expression with the increase in 
DCIS grading in adjacent normal tissue, while it showed a similar expression level to 
the control in tumor tissue. For Erbb2, it showed an increase in expression with the 
increase in DCIS grades in both tumor and adjacent normal tissue. 
While for the IHC analysis, both ETV6 and Erbb2 showed significant protein 
expression level difference in different DCIS grades in tumor tissues according to 
chi-square test analysis. Similar significance was not observed with the application of 
the same statistical analysis on the adjacent normal tissues. 
From the previous chapters, ETV6 and Erbb2 showed potential to be markers for 
DCIS in tumor tissues. 
8 1 
ETV6 
ETV6, also known as TEL, encoded an ETS family transcription factor with a 
repressor activity (Lopez et al, 1999). Its gene product consisted of two functional 
domains: the N-terminal pointed domain was responsible for the protein-protein 
interaction, while the C-terminal was the DNA-binding domain. Studies showed that 
ETV6 was required for hematopoiesis and maintenance of the developing vascular 
network (Barjesteh et al, 2005). 
Whilst the role of ETV6 in breast cancers remains to be elucidated, its roles in pre-B 
acute lymphoblastic leukaemia (ALL) cases were well published. In 26-47% ALL 
cases showed deletions at chromosome 12pl2-13 (Boily el al, 2007) suggested the 
presence of a tumor suppressor gene (TSG) in the region (Stegmaier et al, 1995). 
Indeed, the presence of 12pl2-13 tumor suppressor locus was being seen also in solid 
tumor including breast, lung, ovarian and prostate carcinomas (reviewed in Aissani et 
al, 1999). According to published genetic and functional evidence, ETV6 indicated a 
high likeliness TSG targeted by the deletions (Montpetit et al’ 2004). 
In the genetic aspect, a mutational study revealing the shortest commonly deleted 
region between markers D12S89, which accommodated ETV6 and the polymorphism 
in the third exon of BCL-G indicated these two genes as candidates responsible for 
the tumor suppressor function in the deleted 12pl2-13 region (Montpetit et al, 2004). 
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However, considering the absence of BCL-G in the existing pre-B ALL cases and 
extremely low expression level in leucocytes (Guo et al, 2001), ETV6 remained the 
most potential tumor suppressor gene. 
Upon the construction of a genetic and physical map of the mentioned deleted region 
in pre-B ALL cases, a total of eight candidate genes located in that region (Montpetit 
et al, 2002). While another RNA expression study revealed inactivation of ETV6 on 
both alleles among the eight candidate genes located in that region (Montpetit et al, 
2004) giving further evidence that ETV6 was of the highest candidacy. 
Functions of ETV6 included cell adhesion and maintenance in cellular matrix. In an in 
vitro study, ETV6 demonstrated aggregation phenotypes which seem to be attributable 
to proteins of the cell adhesion and maintenance in cellular matrix (Rompaey et al, 
2000). This theory is supported by a study of the NIH 3T3 cell line, of which the 
ETV6 repressed a gene coding a matrix metal loproteinases, namely 
stromelysin/MMP3, suppressing tumor invasion and metastasis upon the loss of this 
protein (Fenrick et al, 2000; Johansson et al, 2000). To further confirm the results, the 
research team overexpressed ETV6 in the NIH 3T3 cells, injecting into nude mice, 
and found that invasion was highly reduced and completely inhibited metastasis when 
comparing with control. This sheds light in the design of gene therapy in cancer 
clinical treatment. 
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ETV6 was also reported responsible for transcription through interaction with a panel 
of genes through a microarray analysis (Boily et al, 2006). Among the 87 
non-redundant genes being studied, 62 were down regulated and 25 were upregulated. 
Considering the majority of the genes downregulated, the results agreed with another 
study of the transcriptional repressing activity of ETV6 recruiting co-repressors 
including HDAC3, mSin3A, NcoR and SMRT (Kuwata et al, 2002). 
ETV6 is also involved in angiogenesis. When ETV6 was overexpressed in NIH 
3T3-UCLA, vessel-shaped aggregates were formed and showed its relevancy in 
physiological vessel formation (Van Rompaey el al, 2002). 
ETV6 showed to repress antiapoptotic protein BC1-XL, which contributed to apoptosis 
induction (Irvin et al, 2003). However, ETV6 was shown to repress apoptosis when a 
study of the ETV6-knock out mice illustrated excess apoptosis of mesenchymal and 
neural cells (Wang et al, 1997), and another study showing haematopoietic stem cells 
survival is dependent on ETV6 (Hock et al, 2004) lurther suggested the role of ETV6 
in .apoptosis repression. 
The involvement of ETV6 in slow cellular growth and proliferation inhibition when a 
study using ETV6 overexpressed NIH 3T3 cells, ETV6 retarded growth of the cells as 
lowered capacity of colony was formed in soft agar (Fenrick et al, 2000). Another 
study demonstrated an increased proportion of cells in GO/Gl when mouse embryo 
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fibroblasts were traiisfected by ETV6 (Rompaey et al, 2000). Similar results were also 
seen the myeloid leukaemia cell line K562 and the pre-B ALL cell line REH (Sakurai 
et al, 2003) when transfected by ETV6. Growth of tumors was retarded in mice graft 
models and the encouraging shed light in the potential of ETV6 in clinical 
applications (Rompaey et al, 2000). The role of ETV6 in tumor suppression was 
supported. 
ETV6 was also reported to be fused to various partner genes in hematologic 
malignancies with 12pl3 aberrations (Strehl et al, 2008). 
Recent studies demonstrated ETV6 gene rearranges and harbours the t(12;15) 
ETV6/NTRK3 fusion oncogene translocation in congenital fibrosarcomas, cellular 
mesoblastic nephromas and acute myeloid leukaemia (Lannon et al, 2005). While for 
breast cancer, this translocation was observed only in secretory carcinomas so far 
(Makretsov et al, 2004). In a recent study regarding the hypothesized acinic cell 
carcinomas progression to secretory carcinomas was due to the ETV6 rearrangements, 
fluorescence in situ hybridization was performed looking for ETV6/NTRK3 
translocation as a result of that (Reis-Filho et al, 2008). Despite results showed an 
unlike biological continuum from acinic cell carcinomas to secretory carcinomas, 
similar studies could be done to look for biological potential for the DCIS 
progression. 
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Then ETV6 was also fused with NC0A2, a transcriptional coactivator, in leukemia 
cases both T-lymphoid and myeloid antigens. In leukemia cases expressing 
ETV6-NCOA2, there was a high frequency of heterozygous activating NOTCH 1 
mutations, which disrupt the heterodimerization or the PEST domains. Thus it was 
suggested that leukemia cases with ETV6-NCOA2 was associated with a higher 
chance of occurrence of NOTCH 1 mutations (Strehl et al, 2008). 
In some leukemia cases, it was suggested that ETV6-RUNX1 was an early event 
developing from the embryonic or infant stage and later developed into leukemia with 
the acquisition of MLL aberrations, loss of ETV6 function, and duplication of 
ETV6-RUNX1 in further stage. Thus it was suggested that the coexisting 
ETV6-RUNX1 and MLL aberrations could be a subtype of ALL (Amare et al, 2008). 
Studies also showed that some leukemia cells expressed both ETV6-TTL and 
TTL-ETV6, with the latter being the predominant fusion transcript, a 530aa fusion 
protein with 89aa of the N-terminal TTL fusing to the helix-loop-helix domain and 
ETS-binding domain of ETV6. The role of ETV6 in leukemia and the function of 
TTL could be elucidated to gain insight in this aspect (Qiao et al, 2003). 
To conclude, ETV6 showed to modulate cancer-related genes with known functions in 
cell adhesion/cellular matrix, angiogenesis, apoptosis and cell growth/proliferation 
(Boily et al, 2006). Also, ETV6 fused to various partner genes in hematologic 
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malignancies with 12pl3 aberrations. 
From the observation in the project, ETV6 showed a generally higher expression than 
normal and an increase in expression with the DCIS grades in adjacent normal tissues; 
while its expression level was similar to control in tumor tissues. These results indeed 
match with the previous findings of the role of ETV6 as a tumor suppressor gene. A 
loss of this function resulted in tumor development. 
In the IHC analysis, IHC intensity showed significance difference in different DCIS 
grades in tumor tissue, but not in the adjacent normal tissue. With this observation, the 
following hypothesis is put through: in adjacent normal tissues, despite the increasing 
mRNA level across grades, IHC results did not indicate a significant relationship 
between low and high grade DCIS cases from the chi-square analysis. However, the 
number of cases with high IHC signal intensity was indeed generally higher than low 
grade DCIS cases. It is hypothesized that efficiency of translation to ETV6 mRNA to 
protein was lowered due to the presence of tumor. However, significance was shown 
from the chi-square test between the IHC signal intensity and different DCIS grades. 
With the observation of the generally lowered ETV6 expression as shown in real-time 
results, the following hypothesis is put through: despite the low mRNA expression 
level, however considering the importance of cell differentiation, posttranslational 
modifications, such as phosphorylation and sumoylation, can target the impairment of 
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repressions of ETV6. This theory was supported by the publication of a research team 
(Roukens et al 2008). Also, there might be a modification of microenvironment and 
initiated active translation to take place, resulting in a significant difference in ETV6 
IHC signal intensity in different DCIS grades in tumor tissues. 
Therefore, a few approaches could be considered to elucidate the possibility of ETV6 
being a marker for DCIS progression. 
1. Fluorescence in situ hybridization - ETV6 rearrangement was hypothesized in 
acinic cell carcinomas progression to secretory carcinomas, though remained to be 
revealed, this arrangement could be looked for in FFPE DCIS samples (Reis-Filho et 
al, 2008). 
2. Cell culture - to over express, or to knock out ETV6 to study the cells' behavior in 
difference approaches such as viability or apoptosis, so as to study the functional 
pathway of ETV6 to gain insight in DCIS progression. Western blot could be used to 
quantify the ETV6 protein expressed and correlation might be established between 
DCIS progression and ETV6 expression. There are also some breast cancer cell lines 
like T47-D (Auer et al, 2008), Adr-MCF-7 (Jiang et al, 2008) or MDA-MB-231 (Feng 
et al, 2008) available for studies. Since ETV6 plays essential roles in cell 
differentiation and direcetly or negatively regulate gene expression, it is important to 
decipher mechanisms that regulate their activities to understand tumor progression 
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and development (Roukens et al 2008). 
3. Xenograft — to overexpress, or to knock out ETV6 in transgenic mice with breast 
cancer, then extract their breast tissues and study the adjacent normal and tumor 
tissues, especially the microenviroiiment in the former, if any, which favor tumor 
development. Similar study applied this technique in studying secretion of 
pleiotrophin stimulated breast cancer progression through remodeling of the tumor 
microenvironment and proved to be successful (Chang et al, 2007). Also, it is 
suggested that overexpression of ETV6 suppressed tumor invasion (Fenrick et al, 




In breast cancer, the human epidermal growth factor receptor 2 (Erbb2), also known 
as HER2 or c-neu, amplification could be found in about 20% to 30% of cases and 
usually associates with hormone receptor-negative disease and unfavorable outcomes 
(Sundvall et al, 2008). Erbb2 belongs to the receptor tyrosine kinase superfamily, of 
which this superfamily encodoes also Erbbl, i.e. the epidermal growth factor (EGRF), 
Erbb3 and Erbb4 (Jeong et al, 2008). 
The above mentioned receptors comprised of three regions: an extracellular 
ligand-binding region, a single membrane-spanning region and a cytoplasmic tyrosine 
kinase-containing domain (Hynes and Lane, 2005).Upon binding with the ligand, the 
four receptors will then form receptor homo- and hetero-dimers to stabilize ligand 
binding and enhance kinase-mediated activation of downstream signalling pathways 
through phosphorylation on specific tyrosine residues within the cytoplasmic tail. It is 
because upon phosphorylation, proteins could dock on the residues and these recruited 
proteins activate various intracellular signaling pathways. With the homo- and 
hetero-dimers formed by the receptors, the extracellular ligands could be diversified 
and signals could be amplified signals. Study has shown that the hetero- Erbb2 
dimerization with other Erbb receptors is the preferred combination, for example, 
Erbb2-Erbb3 dimer is involved in mitogen-activated protein kinase and 
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phosphatidylinositol-3 kinase (Olayioye et al., 2000). In addition, Erbb2 is shown to 
be the most potent of all kinase domains in the Erbb family of which can be activated 
without ligand association (Di Fiore et al., 1990). 
In addition to dimerization, multiple ligands is able to bind and activate Erbb 
receptors, inducing phosphorylation of cellular substrates mediating increased DNA 
synthesis, cell proliferation, angiogenesis, metastasis, and resistance to apoptosis 
(Emanuel et al., 2008). All the signals induced showed to be crucial mediators of cell 
proliferation and differentiation which are highly correlated with development and 
invasiveness of different types of cancers (Jeong el al., 2008). 
Amplification or overexpression of this gene has been reported in numerous cancers, 
including head and neck, brain, non-small-cell lung cancer breast and ovarian tumors 
(Chakraborty et al., 2008). A publication has hypothesized that overactivity of 
downstream signal transduction leads to uncontrolled cell growth, oncogenesis 
(Libermanm et al., 1985), or cellular transformation (Hudziak et al., 1989). Thus 
Erbb2 overexpression is accompanied with shortened survival and growth regulation 
of the tumors (Slamon et al., 1987). 
The generation of mouse models allowed the study of Erbb2-induced mammary 
tumorigenesis and increased the clinical knowledge in relationship between Erbb2 and 
breast cancer (Ursini-Siegel et al., 2007). The rat homologue of Erbb2 is namely the 
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NEU, identified from chemically-induced neuroblastomas and shown to be 
homologous to retroviral oncogene Erbb2 (Shih et al., 1981). A lot of target genes in 
concert with Erbb2 to promote breast cancer are being revealed, give rise to various 
diagnostic tools and therapeutics development. 
In sight of the overexpression of Erbb2 in development of tumors, and with animal 
models showing the down-regulation of Erbb2 suppress tumor growth and 
dissemination (Drebin et al., 1986). There are a number of therapies targeting the 
down-regulation of Erbb2 in cancer treatments, especially in breast cancer. 
First, it is the treatment with trastuzumab (Herceptin), which is the first approved 
monoclonal antibody treatment for breast cancer, giving significant improvement in 
metastatic Erbb2 patients' survival when used in combination with chemotherapy 
(Slamon et al., 2001). This is achieved through the inhibition of MAPK and PI3K 
signaling pathways which promotes cell cycle arrest and induces apoptosis by 
mediating the internalization and degradation of Erbb2 receptor (Sliwkowski et al., 
1999). However, the use of trastuzumab is seen sometimes accompanied with side 
effects ill some patients including increased risk of cardiac dysfunction with 
symptoms of congestive heart failure (Jeong et al, 2000). This might due to the 
hypothesized function of Erbb2 in cardiac development during embryogenesis and as 
a survival factor in adult myocardium leading to the cytotoxic side effect of 
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trastuzumab (Crone et al., 2002). 
Apart from trastuzumab, research suggested some potential drugs for treating breast 
cancers, for example, quercetin. From a study on SK-Br3 breast cancer cells, the 
anti-tumor activity of quercetin is given by the inhibition of tyrosine kinase activity of 
Erbb2 and induction of ubiquitinylation, which in turn recruits the E3-ubiquitin ligase 
CHIP, the ubiquitinated Erbb2 protein is then degraded by the proteasome thus Erbb2 
is being downregulated (Jeong et al., 2000). Together with showing of quercetin with 
anti-tumor, anti-flammatory, anti-allergic and anti-viral activities, these further proved 
the potential of quercetin for breast cancer treatment (Middleton and Kandaswami, 
1994; Wang, 2000). 
The second suggested treatment is the use of diosgenin to down-regulate Erbb2 
through regulation of fatty acid synthase (FAS). It is because study has shown Erbb2 
regulates FAS expression through PI3K/Akt signal transduction pathways in breast 
cancer cells (Kumar-Sinha et al.，2003). In another neu-N transgenic mice model, 
inhibition of FAS preferentially induced apoptosis of Erbb2 overexpressing cancer 
cells (Menendez et al., 2004) and delayed tumor progression (Alii et al., 2005). This 
suggested the upregulation of FAS expression might play a role in Erbb2-mediated 
cell survival and tumorigenesis (Chiang et al., 2007). Also, inhibition of FAS with 
synthetic inhibitors or siRNA is selectively cytotoxic to human cancer cell and leads 
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to a significant anti-tumor effect in various cancer xenografts (Bandyopadhyay et al., 
2006). These give support for the use of diosgenin, targeting downregulation of FAS, 
as therapeutic implications in Erbb2 overexpressing cancer cells. 
Another potential drug named decorin, a member of the small leucine-rich 
proteoglycan gene family. It has the ability to downregulale members of the Erbb and 
attenuates their signaling, leading to growth inhibition in a breast cancer xenograft 
study. Upon detection by novel species-specific DNA detection and quantitative 
assays, decorin showed further prevention of metastatic spreading to the lungs if 
applied systemically (Goldoni S. et al., 2008). 
Co-expression of breast tumor kinase (PTK6) with Erbb2 gives the scientists another 
insight in breast cancer treatment. Expression of PTK6 enhances the Erbb2-induced 
activation of Ras/MAPK signaling and cyclin E/cdk2 activity, inducing cell 
proliferation in culture. Also, the expression of PTK6 shortens latency of 
Erbb2-induced tumors by promoting cell proliferation without apoptosis protection. 
Therefore, apart from directly targeting Erbb2, drugs targeting PTK6 could be another 
approach for breast cancer treatment (Xiang el al., 2008). 
In regard of the field of coexpression, extensive study has performed on Erbb2-EGFR 
heterodimer which lead to amplification of signal transduction (Olayioye et al., 2000). 
With clinical evidence showing cancers overexpressing both receptors have a worse 
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outcome than overexpressing either receptor (Osaki A. et al., 1992; Lorenzo GD. et 
al., 2002), it could be explained by the heterodimerizalion crosstalk stimulating 
synergistic mitogenicity and invasiveness (Brandt et al., 1999). In a recent study, a 
new dual EGFR and Erbb2 inhibitor, MP-412 (AV-412) showed significant antitumor 
effects on both EGFR- and ErbB2-overexpressing cancer xenografts (Suzuki et al., 
2007). Therefore the dual inhibitor of EGFR and Erbb2 suggested an alternative 
therapy for patients expressing both receptors. 
Reasons for Erbb2 overexpression include gene amplification, increased mRNA labels 
or overproduction of Ertbb2 protein (Dalifard et al, 1998). While from the 
observation of the project, Erbb2 showed an increase expression level with an 
increase in DCIS grades in both adjacent normal and tumor tissues according to the 
real-time PCR results. Since Erbb2 was a known marker for breast cancer including 
DCIS, as mentioned in section 1.4.3.2, its increase in expression across DCIS grades 
was not unexpected. But it was interesting to observe similar increase in expression in 
the adjacent normal tissues across DCIS grades, since literature mostly include Erbb2 
expression data in tumor tissues. A possible reason for this phenomenon could be the 
Erbb2 expression in tumor tissue influences also the Erbb2 expression in adjacent 
normal tissues, promoting an environment which favors tumor development, and 
perhaps explained Erbb2 over expression led to unfavorable outcomes. Upon this 
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observation, Erbb2 has certain potential serving as a marker in adjacent normal tissues 
in DCIS and this hypothesis does worth looking into. 
In the IHC analysis, Erbb2 signal intensity showed a significant expression pattern in 
different grades of DCIS tumor tissues, but not in adjacent normal tissues despite their 
similarity in expression level as shown in real-time PCR. Since Erbb2 tend to form 
heterodimer in order to activate downstream signalling pathways in tumor 
development, it is hypothesized that in adjacent normal tissues, translation to Erbb2 
protein is being hindered or compressed, such heterodimer could not be formed and 
yet remained to become tumor. Also, the overexpression of Erbb2 is shown correlated 
with coexpression with various genes, such as the above mentioned PTK6 or FAS, a 
clearer picture might be provided with the inclusion of the study of those genes in the 
adjacent normal tissues. 
The significance of the observation included also the validity of this project since 
Erbb2 is a known marker for DCIS (Vincent-Salomon el al, 2008). Then with this 
background information, focus should be put on the Erbb2 expression in adjacent 
normal tissues as there are few studies in this area. Some suggested follow up work 
would be: 
1. Cell culture: construct normal breast cell line over expressing Erbb2 and 
construct breast tumor cell line over expressing Erbb2, look for, if any, the 
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modification of the microenvironment in the normal cells and breast tumor cells. It 
was because tumor microenvironment was shown contributed to breast cancer 
progression (Chang et al, 2007) 
2. Tissue culture: compress the Erbb2 expression in adjacent normal tissues, while 
overexpress Erbb2 in tumor tissue. Then compare the breast cancer development with 
breast cancer tissues and adjacent normal tissues over expressing Erbb2. If aggressive 
tumor development is being observed in breast cancer tissues and adjacent normal 
tissues over expressing Erbb2, then Erbb2 could be concluded to play a role in tumor 
progression, thus provide a glimpse in DCIS progression. 
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Clinical application of ETV6 and Erbh2 
The morale for the treatment of DCIS is to first to give a precise diagnosis of DCIS 
and optimize the clinical treatment for the patients to prevent it becoming invasive 
breast cancer. However, under conditions including insufficient sample amount, 
non-representative tissue extraction, or contradiction between pathological finding 
and imaging result due to limitations in technology or surgical procedures, might not 
be representative to give precise diagnosis on the DCIS tumor grade. Also, the 
extraction of the adjacent normal tissue would be unable to provide an accurate 
clinical feature for pathological diagnosis. Considering the potential function of ETV6 
and Erbb2, their expression patterns and IHC signal intensity could serve with clinical 
applications. 
For the use of the real-time PCR results, it is especially useful in cases where the 
adjacent normal tissues were extracted instead of the tumor tissues. It is because the 
ETV6a expression of tumor was fairly low or similar to control, rather, the ETV6a 
expression level appeared more informative. With the use of the same setup and the 
established figures of the ETV6a expression level of the control samples, the ETV6a 
expression level of the extracted tissue could be revealed. The comparison between 
the expression level of the extracted tissue to the ETV6a expression levels from the 
graph in Fig. 4.1 could be served as a reference for the diagnosed grade. 
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It is because from Fig. 4.1, "low grade" DCIS cases showed about 1-fold increase in 
ETV6a expression level. Then from the graph, Grade II and Grade III DCIS cases (i.e. 
"high grade" cases according to the grouping of DCIS cases in the study) showed 
about 1.5-fold and 3-fold increase in ETV6a expression level. It could be concluded 
that for cases showing about l-fold increase would be a low grade DCIS case, while 
1.5 or more fold of increase in ETV6a expression level would likely be a high grade 
DCIS case. 
Therefore in sight of the range of fold increase of which the extracted tissues falls into, 
a reference for the diagnosed DCIS grade could be obtained and hopefully to optimize 
the treatment for the patient. For example, when a low grade case indicating a more 
than a 1.5 to 3-fold increase in ETV6a expression level, this particular case could 
have a high grade DCIS parameter and might opt for a more extensive treatment. 
While of a high grade DCIS case with an about 1-fold increase in ETV6a expression 
level, this particular case could have a low grade DCIS parameter and might opt for a 
conservative treatment. 
On top of the above implication, in cases when insufficient amount of tumor tissues 
samples were extracted, PCR could be performed to predict the probability of an 
accurately diagnosed grade according to the presence or absence of the PCR bands 
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when running with ETV6a primers. With the z value calculated from the equation z -
2.339-0.339*ETV6a expression (p=0.033) and transformed the z value with 1/(1+ 
e'z ), the probability of an accurately diagnosed DCIS grade could be obtained and 
served as a reference when considering an appropriate treatment for the patient. 
Also, from the results obtained from the IHC analysis, a significant relationship was 
established between IHC signal intensity and DCIS grading. As shown in the equation 
z = 2.339-0.339*ETV6a expression (p=0.033), the negative coefficient of ETV6a 
expression (i.e. -0.339) indicated a negative relationship between ETV6a expression 
and DCIS grades (i.e. ETV6a expression decreases with an increase in DCIS grades 
and vice versa). The implication of these results could be when low grade cases, with 
a supposing high ETV6 IHC signal intensity, but indicting a low ETV6 IHC signal 
intensity from immunostaining, it could have a possibility that the case would have a 
high grade parameter and should consider a more extensive treatment. Or when there 
are high grade cases, with a supposing low ETV6 IHC signal intensity, but indicting a 
high ETV6 IHC signal intensity from immunostaining it could have a possibility that 
the case consisted of a low grade parameter and should consider a more conservative 
treatment. 
Besides together with the application of the expression levels or IHC intensity of 
Erbb2, a known marker for breast cancer, could provide further reference when 
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considering treatment for DCIS patients. 
In the real-time PCR results, the Erbb2 expression showed similar expression pattern 
in adjacent normal tissues and tumor tissues, so the Erbb2 expression level of the 
extracted samples, whether it was the extraction of the adjacent normal or tumor 
tissues, could serve as another indicator for the DCIS grading of the DCIS case. 
Similar to the mentioned method above, with the use of the same setup and the 
established figures of the Erbb2 expression level of the control samples, the Erbb2 
expression level of the extracted tissue could be revealed. The comparison between 
the expression level of the extracted tissue to the Erbb2 expression levels from the 
graph in Fig. 4.2 could be served as a reference for the diagnosed grade. 
It is because from Fig. 4.2，"low grade" DCIS cases showed about 3-fold increase in 
Erbb2 expression level. Then from the graph, Grade II and Grade III DCIS cases (i.e. 
"high grade" cases according to the grouping of DCIS cases in the study) showed 
about 7-fold and 10-fold increase in Erbb2 expression level. It could be concluded 
that for cases showing about 3-fold, or less, of increase in Erbb2 expression level 
would likely be a low grade DCIS case; while 7 or more fold of increase in Erbb2 
expression level would likely be a high grade DCIS case. 
According to the range of fold increase of which the extracted tissues falls into, a 
reference for the diagnosed DCIS grade could be obtained and hopefully to optimize 
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the treatment for the patient, especially when the pathological finding did not agree 
with imaging results. For example, when a low grade case indicating a more than 
7-fold Erbb2 expression level, this particular case could have a high grade DCIS 
parameter and might opt for a more extensive treatment. While for a high grade DCIS 
case with an about or less than 3-fold, in increase in Erbb2 expression level, this 
particular case could have a low grade DCIS parameter and might opt for a more 
conservative treatment. 
Sometimes due to limitation of technology, only insufficient amount of tumor tissues 
samples could be extracted. For cases encountering this situation, PCR analysis could 
be performed to predict the probability of an accurately diagnosed grade according to 
the presence or absence of the PCR bands when running with both ETV6a and Erbb2 
primers. It is because from the statistical analysis, the z value calculated from the 
equation z = 1.522-0.259*ETV6a expression + (U75*Erbb2 expression (p=0.031) 
could provide a more significant prediction of DCIS grade. Thereon when 
transforming the z value with 1/(1+ e"'' ), the probability of an accurately diagnosed 
DCIS grade could be obtained and served as a reference when considering an 
appropriate treatment for the patient. 
Also, from the results obtained from the IHC analysis, a significant relationship was 
1 0 2 
established between Erbb2 IHC signal intensity and DCIS grading. As shown in the 
equation z = 1.522-0.259*ETV6a expression + 0.175*Erbb2 expression (p二0.031), 
the positive coefficient of Erbb2 expression (i.e. +0.175) indicated a positive 
relationship between Erbb2 expression and DCIS grades (i.e. Erbb2 expression 
increases with an increase in DCIS grades and vice versa). The implication of these 
results could be when low grade cases, with a supposing low Erbb2 IHC signal 
intensity, but indicting a high Erbb2 IHC signal intensity from immunostaining, it 
could have a possibility that the case would have a high grade parameter and should 
consider a more extensive treatment. Or when there are high grade cases, with a 
supposing high Erbb2 IHC signal intensity, but indicting a low Erbb2 IHC signal 
intensity from immunostaining it could have a possibility that the case consisted of a 
low grade parameter and should consider conservative treatment. 
With the illustrations above, the expression pattern of ETV6 and Erbb2 do have a 
potential to serve their clinical applications as a reference for the pathologist together 
with the clinical findings, and hopefully to optimize the clinical treatment for DCIS 
patients. 
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Modification of the Van Nuys Prognostic Index 
The VNPI was widely used to predict the likeliness of recurrence, instead of the 
biological potential of DCIS. However, the information provided by the ETV6 and 
Erbb2 could have the potential to compensate this short coming of VNPI. 
It was because for ETV6, a lower in expression as shown in real-time PCR was seen 
in the tumor tissues, indicated a likeliness that a lower in expression played a role in 
tumor development. Then for the significant high ETV6 intensity signal expression 
pattern showed in high DCIS tumor tissues, it indicated a high ETV6 protein 
expression had potential in contributing to tumor development as this significant 
expression was not seen in the adjacent normal tissues. 
With this hypothesis, further studies could be made aiming to establish a correlation 
between molecular data of ETV6 and clinical grading as indicated in the VNPI. 
While for Erbb2, it had similar results in both adjacent normal and tumor tissues 
shown from the real-time PCR, but an insignificant high protein expression in the 
adjacent normal tissues. This showed a potential increase of protein expression 
resulted in tumor development. 
If this hypothesis was verified, with the use of both the Erbb2 expression level 
adjacent normal and tumor tissues according to the real-time PCR, and protein 
expression level, it could definitely provide molecular data to the VNPI to give a 
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better prediction of the DCIS progression to invasive tumor 
Overall summary 
This project aimed to provide a preliminary screening for the potential DCIS markers 
which could give insight in DIGS progression. Upon the quantification of gene 
expression level and IHC studies, ETV6 and Erbb2 demonstrated a potential to serve 
as a DCIS markers. 
Upon gaining more information regarding these potential markers, it is hopeful to 
optimize treatment for DCIS patients to prevent DCIS progression to invasive breast 
cancer. All this information consolidated the background information and set a 
milestone for further studies. 
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